Gapping down
In reaction to disappointing earnings/guidance: SNX -1.3%, FUN -1.2%.
Select metals/mining stocks trading lower: SSRI -2%, GDX -1%, SLV -0.9%, AG -0.8%, GG -0.7%, ABX -0.7%, GLD -0.6%, KGC -0.5%.
Other news: RGDO -53.7% (announces initiation of DSMB review of REGULATE-PCI data), NQ -17% (announced certain changes to its Board of Directors and provided a status update on its 2013 annual audit), TKMR -14.5% (receives notice of clinical hold for TKM-Ebola Phase I Clinical Trial), BIND -10.7% (announced today the completion of its collaborative research program with Amgen),BIND -10.7% (announced the completion of its collaborative research program with Amgen (AMGN); companies will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload), RGSE -9.7% (has entered into a definitive agreement to raise ~$7.0 mln in a private placement financing transaction), USU -5.3% (pulling back following yesterday's advance), PBR-1.3% (still checking), AZC -0.6% (co and Hudbay Minerals (HBM) announce filing of offer documents for friendly acquisition).
Analyst comments: RMD -1.6% (downgraded to Hold from Buy at Deutsche Bank), RSPP -1.5% (downgraded to Neutral from Buy at UBS), ERIC -1.2% (initiated with a Hold at Jefferies), AZN -0.9% (resumed with a Underweight at JP Morgan).
Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz36PLG4q3i
In reaction to disappointing earnings/guidance: SNX -1.3%, FUN -1.2%.
Select metals/mining stocks trading lower: SSRI -2%, GDX -1%, SLV -0.9%, AG -0.8%, GG -0.7%, ABX -0.7%, GLD -0.6%, KGC -0.5%.
Other news: RGDO -53.7% (announces initiation of DSMB review of REGULATE-PCI data), NQ -17% (announced certain changes to its Board of Directors and provided a status update on its 2013 annual audit), TKMR -14.5% (receives notice of clinical hold for TKM-Ebola Phase I Clinical Trial), BIND -10.7% (announced today the completion of its collaborative research program with Amgen),BIND -10.7% (announced the completion of its collaborative research program with Amgen (AMGN); companies will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload), RGSE -9.7% (has entered into a definitive agreement to raise ~$7.0 mln in a private placement financing transaction), USU -5.3% (pulling back following yesterday's advance), PBR-1.3% (still checking), AZC -0.6% (co and Hudbay Minerals (HBM) announce filing of offer documents for friendly acquisition).
Analyst comments: RMD -1.6% (downgraded to Hold from Buy at Deutsche Bank), RSPP -1.5% (downgraded to Neutral from Buy at UBS), ERIC -1.2% (initiated with a Hold at Jefferies), AZN -0.9% (resumed with a Underweight at JP Morgan).
Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz36PLG4q3i